Mirtazapine Arrow

Mirtazapine, the active ingredient in Mirtazapine Arrow, is a Noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms, improves mood, sleep and appetite.

Mirtazapine may cause a range of adverse reactions, from frequent to rare.

Common Side Effects: - Sedation: drowsiness, especially at treatment initiation. - Increased appetite: may lead to weight gain. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness on standing. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Stevens‑Johnson syndrome: serious skin reaction. - Hepatic dysfunction: elevated liver enzymes. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Severe hypotension: marked drop in blood pressure. - Neuroleptic malignant‑like syndrome: rare but life‑threatening condition.

Before initiating therapy, clinicians should consider several safety aspects.

- Pregnancy: Category C; evaluate risk‑benefit ratio with prescriber. - Elderly patients: monitor for excessive sedation and fall risk. - Hepatic impairment: dose adjustment may be required. - Concomitant CNS depressants: may enhance sedative effects. - Suicidal ideation: close monitoring during early treatment. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Linezolid or other reversible MAO‑A inhibitors: potential serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs): increased serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, alcohol): enhanced sedation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine levels. - Antihistamines: additive anticholinergic effects. - Diuretics: possible additive hypotensive effect.